Total trials
127
Active
39
Phase 3
5
Total enrollment
952,634
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy | — | — | — | — | — | 1 | |
| Lymecyclin and corresponding placebos of the experimental arm | — | — | — | — | — | 1 | |
| blood samples collection | — | — | — | — | — | 1 | |
| Nasopharyngeal swab | — | — | — | — | — | 1 | |
| Blood samples | — | — | — | — | — | 1 | |
| Blood sample collection | — | — | — | — | — | 1 |
Next readouts
- 2025-11-16
- 2026-03-15
- 2026-04-30
- 2027-02-28
Top conditions
- COVID-196
- Dengue5
- Healthy Volunteers4
- Leptospirosis4
- Arbovirus Infections4
- Chikungunya4
- Covid193
- Malaria3
Frequently asked questions about Institut Pasteur
- How many clinical trials does Institut Pasteur have on ClinicalTrials.gov?
- Institut Pasteur is listed as the lead sponsor on 127 clinical trials in ClinicalTrials.gov, 39 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Institut Pasteur's trials are in Phase 3?
- 5 of Institut Pasteur's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Institut Pasteur focus on?
- Institut Pasteur's most-studied conditions on ClinicalTrials.gov are COVID-19, Dengue, Healthy Volunteers, Leptospirosis, Arbovirus Infections.
- When are Institut Pasteur's next clinical trial readouts?
- Institut Pasteur has 4 upcoming primary-completion readouts tracked here; the soonest is “Impact of Bacterial Expression and Immune Response in the Severity of Pertussis”, expected around 2025-11-16.